Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsDenver Health Medical Plan Formulary Coverage & PA…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentDenver-Health-Medical-PlanPolicy N/A

    Formulary and Prior Authorization Guidelines for Outpatient Drugs

    Customize your policy alerts

    Sign up for all Denver-Health-Medical-Plan policy alerts

    Know when Denver-Health-Medical-Plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs the Denver Health Medical Plan Elevate outpatient pharmacy formulary, including tier definitions, prior authorization, generic substitution, exclusions, and medication request processes for members and providers.

    Policy Summary
    PayerDenver-Health-Medical-Plan
    PolicyFormulary and Prior Authorization Guidelines for Outpatient Drugs
    Policy CodePolicy N/A
    Change TypeMinor / No material change
    Effective DateOct 1, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization or document prior prescription history when a drug's Notes indicate PA or ST (commonly prior trials within 120 days) and follow specified quantity limits.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Tier 1-6Defined formulary tiers
    Tier 5/6Specialty placement
    ST/PA/QLUtilization controls
    No costContraceptive coverage
    PresentAge limits

    Formulary Coverage & Prior Authorization Rules

    Formulary Coverage and Prior Authorization

    Covered outpatient medications are listed on the formulary; use of FDA‑approved generics is required when available. Prior authorization (PA) applies where the formulary Notes indicate and requests are reviewed per P & T guidelines.

    Generic substitution: When available, FDA‑approved generic drugs are to be used; brand products are covered only when listed or when a documented medical need is approved via the medication request process.

    Member may be required to pay the cost difference if a brand is requested without documented medical need.

    Prior authorization overview: Drugs annotated with 'PA' require prior authorization; each PA request is reviewed individually against MedImpact P & T Committee guidelines and will be denied if criteria are not met.

    Fax PA requests to DHMP Pharmacy Department at (303) 602-2081 or contact (303) 602-2070; denied requests may be appealed with supporting medical necessity documentation.

    Nasal antihistamine-steroid combination coverage

    Nasal antihistamine–intranasal steroid combination products are covered when tiering, step therapy, and quantity limits shown on the formulary are satisfied.

    Policy Summary
    PayerDenver-Health-Medical-Plan
    PolicyFormulary and Prior Authorization Guidelines for Outpatient Drugs
    Policy CodePolicy N/A
    Change TypeMinor / No material change
    Effective DateOct 1, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization or document prior prescription history when a drug's Notes indicate PA or ST (commonly prior trials within 120 days) and follow specified quantity limits.
    SourceLink
    On This Page
    Formulary Coverage & Prior Authorization RulesFormulary Items & Coding ReferencesPrior Authorization, Step Therapy & Documentation RequirementsInitial Therapy & Prior-Prescription RequirementsQuantity Limits & Supply RestrictionsPolicy Governance & RationaleKey Terms & Abbreviations
    Dymista (azelastine‑fluticasone) coverage: Coverage requires evidence of a prior prescription for flunisolide (nasal) or fluticasone within the past 120 days and adherence to the product QL.prior RX within 120 days; QL 23 GM per 30 days

    Dymista status and tier vary by presentation; ST and QL noted on formulary.

    Other intranasal corticosteroid/antihistamine combinations: Similar branded nasal combination agents and non‑aerosol intranasal steroid products require step therapy documentation when Notes = ST and must meet the listed QL values per formulary entry.prior RX within 120 days where ST indicated; product‑specific QL

    See QNASL/XHANCE/ZETONNA entries for analogous ST and QL examples.

    Dronabinol and related agents

    Dronabinol and related cannabinoid antiemetics are subject to step therapy and quantity limits as specified on the formulary.

    Dronabinol (Marinol/Syndros) step therapy: Coverage requires prior prescription trials within the past 120 days of a 5‑HT3 antagonist, corticosteroid, aprepitant/Emend, or megestrol suspension as specified; quantity limits apply per day.prior RX within 120 days; QL 2 EA per 1 day (example)

    Syndros notes also reference prior generic dronabinol or megestrol when ST is indicated.

    Inhaled bronchodilators and anticholinergics

    Inhaled bronchodilators and anticholinergics are covered per formulary tiering; certain agents require step therapy or have quantity limits.

    Long‑acting inhaled bronchodilators/anticholinergics: Some products (e.g., Incruse, Tudorza, Brovana) require documentation of a prior prescription for a specified comparator (for example, Spiriva or Perforomist/Serevent/Striverdi) within the past 120 days when ST is indicated.prior RX within 120 days where ST noted; product‑specific QL (e.g., Spiriva QL 30 EA/30 days; Brovana QL 120 ML/30 days)

    Tier assignment and QL vary by product; see product Notes for exact QL values.

    Combination inhalers and ICS products: Combination and inhaled corticosteroid products may require prior prescription for listed comparators (e.g., Advair HFA, Arnuity Ellipta) within 120 days and are subject to QL values shown on the formulary.prior RX within 120 days where ST indicated; QL per product

    Failure to meet ST or exceed QL may trigger denial or PA per formulary guidance.

    Formulary listing with utilization controls

    Formulary line items include tier placement and utilization controls (PA, ST, QL); providers must follow product‑specific Notes.

    Product‑level utilization controls: Each formulary product line displays tier assignment and may include Notes indicating Prior Authorization (PA), Step Therapy (ST) requiring prior prescriptions within defined look‑back periods (commonly 120 days), and Quantity Limits (QL).

    Examples: Brovana ST requiring prior Perforomist/Serevent/Striverdi within 120 days; many biologics and mAbs marked PA.

    Coverage with utilization controls

    Medications are assigned to tiers and may be subject to utilization controls as noted per product entry.

    Tiering plus utilization controls: Medications (Tier 2–Tier 4 shown) are subject to product‑specific prior authorization (PA), step therapy (ST) requiring prior prescriptions within the past 120 days, and quantity limits (QL) as listed.

    Examples include EMSAM (ST with prior MAOI), AUVELITY/VIIBRYD (ST with prior antidepressant trials), and multiple entries with QL values.

    Formulary coverage with utilization management

    Coverage is tiered and numerous agents are subject to step therapy, prior authorization, and quantity limits per product Notes.

    Hypnotics/sleep agents step therapy: For specified hypnotics (e.g., Rozerem, tasimelteon entries), coverage requires prior prescription for Eszopiclone, Zaleplon, or Zolpidem IR within the past 120 days where ST is indicated.120 days

    Many sedative‑hypnotic entries also include QL (commonly 1 EA per day).

    PA‑required agents: Certain agents in this segment (examples: Hetlioz, Sunosi, other narcolepsy agents) are designated 'PA' and require prior authorization before coverage.

    PA annotation appears in product Notes.

    Formulary coverage rules (excerpt)

    Formulary coverage by tier includes explicit utilization management flags (PA, ST) and quantity limits where specified.

    Tier assignment: Drugs are assigned to tiers (Tier 2 through Tier 5) and member cost‑sharing follows tier placement.

    Tier shown per product line.

    Prior authorization (PA): Products annotated with 'PA' require prior authorization prior to dispensing (examples include certain injectables, specialty agents and formulations).

    PA requests reviewed according to P & T guidelines.

    Step therapy (ST): Products with 'ST' require documentation of prior prescription(s) for specified comparator agents within the stated timeframe (commonly 120 days).

    See individual product entries for required comparators and look‑back period.

    Quantity limits (QL): When QL is indicated (examples: Hemangeol 360 mL per 30 days; SOTYLIZE 8 bottles per 30 days), dispensing is limited to the stated quantities unless an exception is approved.

    Exact QL values are listed per product in the formulary.

    Step Therapy / Prior prescription criteria

    Step therapy requires prior trials of specified alternative therapies before coverage of higher‑tier or branded specialty agents.

    PCSK9/ST examples: Repatha: ST requires prior prescription for a generic statin within the past 120 days; Praluent: ST requires prior prescription for Repatha within the past 120 days.prior RX within 120 days

    Specialty biologics and PCSK9 inhibitors may have chained ST requirements.

    Prior Authorization criteria

    Prior authorization is required for many specialty, high‑cost, and select pulmonary agents as noted on the formulary.

    PA examples: Multiple pulmonary antihypertensive and prostacyclin agents (e.g., Adempas, Tyvaso, Remodulin, Flolan, Uptravi) and several biologics/monoclonal antibodies are marked 'PA' indicating prior authorization is required before coverage.

    PA annotation appears next to many specialty agents and formulations.

    Quantity limits

    Quantity limits (QL) are applied to many products and must be observed; some products have concurrent PA or ST requirements.

    Common QL examples: Examples include QL (1 EA per 1 day) for multiple statins/combinations and QL (1 EA per 1 day) noted for other oral agents; specific biologics and long‑acting injectables have QL per dosing interval (per 21 days, per 28 days, etc.).QL values vary by product (see formulary entries)

    Prescribers/pharmacies must document and adhere to QL when dispensing; exceeding QL may require PA or be denied.

    Formulary coverage entries

    Selected formulary coverage entries (contraceptives, devices, dermatology, cough products) illustrate tier/status and product‑specific restrictions.

    Contraceptives and preventive products: Many oral/transdermal/intrauterine contraceptive products are listed with Status = PREV and have QL values where noted (examples: 91 EA per 84 days for 3‑month packs; 28 EA per 28 days for 28‑day packs).QL values as listed per product

    Status = PREV appears throughout contraceptive entries.

    Cough/antitussive products: Selected narcotic and non‑narcotic antitussives (promethazine‑codeine, hydrocodone combinations) include QL and minimum age restrictions (e.g., Age Min 18 Years) and are tiered per formulary entries.QL (ML/EA per day) and Age limits where specified

    Age and QL must be documented at dispensing.

    Dermatology/acne agents: Topical and systemic acne agents are tiered and may carry QL (e.g., isotretinoin QL per formulary) and step therapy requirements for certain topical brands (e.g., ACANYA requires prior generic clindamycin/benzoyl peroxide within past 120 days).ST when noted; QL where listed

    See ACANYA entry for explicit ST requirement.

    The formulary identifies several over-the-counter (OTC) exclusions. Specifically, OTC medications or their equivalents are not covered unless listed on the formulary. Other general non‑covered categories include dietary supplements, drugs used for cosmetic purposes (e.g., anti‑wrinkle, hair removal/growth), blood or plasma products (except anti‑hemophilic factors), pigmenting/de‑pigmenting agents, infertility and weight‑loss drugs, most therapeutic devices or appliances (with the exception of formulary diabetic monitoring supplies), investigational/experimental treatments, drugs explicitly listed as not covered, and foreign‑sourced non‑FDA drugs except where permitted for shortages. Providers are encouraged to contact the plan for alternatives when a need is not met by the formulary.

    Within the provided extract there are no explicit blanket exclusions stated beyond the general exclusions section. The segment presents product listings, tier assignments, and utilization annotations (e.g., PA/ST/QL) but does not enumerate additional universal exclusion categories in this portion of the document.

    This extract does not contain explicit therapeutic‑class exclusions. Drug entries include tiering, quantity limits, and utilization controls (for example, QL and PA flags) but no statements removing whole therapeutic classes from coverage are present in these chunks.

    No explicit clinical exclusions (conditions or diagnoses for which drugs are categorically not covered) are documented in this portion of the formulary. The content focuses on product‑level status, tier placement, PA/ST/QL notes and related dispensing limits rather than clinical exclusion rules.

    In the provided contraceptive and device listings there are no explicit exclusion conditions described. Entries instead emphasize product status flags (many showing Status = PREV) and associated quantity‑limit (QL) notes where applicable, rather than stating exclusion criteria.

    These chunks do not contain explicit coverage exclusions. The material details specific contraceptive product listings, tier/status annotations and quantity‑limit examples (e.g., QL 91 EA per 84 days), but does not present additional exclusion language in this excerpt.

    There are no explicit coverage exclusions in these contraceptive product listings. The entries predominantly show Status = PREV for many products and occasionally list QL notes (for example, 28‑ or 91‑day pack limits), but do not state that products are not covered on clinical or medical necessity grounds in this extract.

    This portion of the formulary does not include explicit not medically necessary determinations. The emphasis in the extract is on tier assignments, utilization controls (Step Therapy/PA/QL) and product‑level notes rather than explicit statements that specific treatments are not medically necessary.

    No explicit not medically necessary rules appear in this segment. Instead, the document lists product‑level utilization controls (e.g., step therapy prerequisites, quantity limits, and PA flags) and describes the documentation and prior‑therapy requirements used to adjudicate coverage.

    These chunks do not state explicit not medically necessary policies. Coverage language in this portion centers on tiering, quantity limits (for example, QL = 1 EA per 1 day for some products), and PA/QL annotations rather than categorical noncoverage statements.

    Formulary Items & Coding References

    Formulary products (no billing codes in this segment)mixed
    NDC/HCPCS not listedFormulary entries list product names and strengths; no explicit CPT/HCPCS/ICD codes provided in this segment
    Formulary products (no billing codes in this segment) - supporting entriesmixed
    Formulary line itemsProduct names and tiers shown (e.g., GRASTEK, ODACTRA, ORALAIR, PALFORZIA) but no explicit billing codes provided in these chunks
    Formulary product entries (no explicit CPT/HCPCS/NDC provided in this segment)mixed
    NDC/Label-level not providedProduct-level entries listed with strengths and forms (e.g., INVEGA SUSTENNA, UZEDY, VERSACLOZ) but no explicit CPT/HCPCS/NDC values in these chunks
    Formulary drug list (partial)mixed
    eprosartan 600 mgeprosartan oral tablet 600 mg
    irbesartan 150 mg, 300 mg, 75 mgirbesartan oral tablet strengths listed
    losartan 25 mg, 50 mg, 100 mglosartan oral tablet strengths listed
    olmesartan 5 mg, 20 mg, 40 mgolmesartan oral tablet strengths listed
    telmisartan 20 mg, 40 mg, 80 mgtelmisartan oral tablet strengths listed
    valsartan 40 mg, 80 mg, 160 mg, 320 mgvalsartan oral tablet strengths listed
    clonidine patch 0.1, 0.2, 0.3 mg/24 hrclonidine transdermal patch strengths listed
    clonidine oral 0.1 mg, 0.2 mg, 0.3 mgclonidine oral tablet strengths listed
    guanfacine 1 mg, 2 mgguanfacine oral tablet strengths listed
    methyldopa 250 mg, 500 mgmethyldopa oral tablet strengths listed
    1–10 of 33
    1/4
    Formulary drug items (sample)mixed
    FUROSCIX SUBCUTANEOUS KIT 80 MG/10 MLFurosemide subcutaneous kit
    LASIX ORAL TABLET 20 MG, 40 MG, 80 MGFurosemide oral tablet
    ALDACTONE ORAL TABLET 100 MG, 25 MG, 50 MGSpironolactone oral tablet
    Pulmonary prostacyclin agentsmixed
    REMODULIN INJECTION SOLUTION 0.4 MG/MLTreprostinil injection solution
    TYVASO DPI INHALATION CARTRIDGE 16 MCGInhaled treprostinil cartridge
    PCSK9 inhibitorsmixed
    PRALUENT PEN SUBCUTANEOUS PEN INJECTOR 150 MG/ML, 75 MG/MLAlirocumab (Praluent)
    REPATHA SURECLICK SUBCUTANEOUS PEN INJECTOR 140 MG/MLEvolocumab (Repatha)
    Formulary limits and age restrictionsmixed
    QL (28 EA per 30 days)Quantity limit example noted for methylergonovine and others
    QL (30 ML per 1 day)Quantity limit example for several syrups (e.g., promethazine-codeine)
    Age (Min 18 Years)Minimum age restriction for selected antitussive/narcotic products
    QL (10 ML per 1 day)Quantity limit example for hydrocodone-chlorpheniramine
    FL: 10 DAYS' SUPPLY PER FILLFlorida-specific fill limit noted for TUXARIN ER
    Quantity limits — representative examples
    DYMISTA (azelastine‑fluticasone) QLQL 23 GM per 30 days; ST: requires prior prescription for flunisolide (nasal) or fluticasone within the past 120 days.
    SANCUSO (granisetron transdermal patch) QLQL 1 EA per 7 days; ST: requires prior prescription for ondansetron tablets/ODT within past 120 days.
    Nebulized inhalation solutions QL examplesBROVANA and PERFOROMIST: QL 120 ML per 30 days; Pulmicort nebulization: QL 120 ML per 30 days.
    Inhaler / blister QL examplesBREO/ADVAIR/ANORO/TRELEGY: typical QL entries include QL 60 EA per 30 days (device/inhaler) or GM/ML per 30 days for metered formulations.
    INVEGA SUSTENNA / TRINZA QL examplesINVEGA SUSTENNA: QL e.g., 0.75–1.5 mL per 21 days depending on strength; INVEGA TRINZA: FL: 90 days' supply per fill; QL values expressed per 70 days.
    Hemangeol (propranolol oral solution) QLQL 360 mL per 30 days; ST: requires prior prescription for generic propranolol oral solution within past 120 days for eligible ages.
    SOTYLIZE (sotalol) oral solution QLQL 8 bottles in 30 days; ST: requires prior prescription for sotalol tablets within the past 120 days.
    Oral solution ENALAPRIL / QBRELIS QLEPANED / QBRELIS oral solution: QL 1200 mL per 30 days (with ST requirement for enalapril/lisinopril tablets in certain pediatric ages).
    Contraceptive dose‑pack QL examples3‑month dose packs (e.g., Camrese Lo, Setlakin, Simpesse): QL 91 EA per 84 days; 28‑day packs (e.g., Minzoya, Slynd): QL 28 EA per 28 days; daily oral contraceptives: QL 1 EA per 1 day.
    Quantity-limit patterns and common units
    QL 120 ML per 30 days examplesBROVANA and PERFOROMIST inhalation solutions: QL 120 ML per 30 days (nebulizer solutions).
    QL 60 EA per 30 days examplesSEREVENT, BREO, and similar inhaler blister devices: QL 60 EA per 30 days for many inhaler/blister products.
    QL expressed in GM per 30 daysAIRSUPRA/BREYNA/BREO/PULMICORT entries show GM or ML per 30‑day limits (e.g., AIRSUPRA QL 32.1 GM per 30 days; BREYNA QL 30.9 GM per 30 days).
    Long‑acting injectable QL per dosing intervalINVEGA SUSTENNA: QL expressed as mL per 21 days (e.g., 0.25–1.5 mL per 21 days depending on strength); INVEGA TRINZA: QL expressed per 70 days and FL: 90 days' supply per fill.
    Hemangeol and SOTYLIZE oral solution QLsHemangeol: QL 360 mL per 30 days; SOTYLIZE oral solution: QL 8 bottles in 30 days.
    Oral solution pediatric QLEPANED / QBRELIS: QL 1200 mL per 30 days when ST/age conditions apply (e.g., requires prior tablet prescription for patients ≥12 years).
    Daily and per‑fill quantity-limit examples
    Per‑day EA limits (common)Multiple CNS and stimulant products list QL as EA per day (examples include QL 1 EA per 1 day; QL 2 EA per 1 day).
    Higher per‑month EA capsSome stimulants and other oral agents use monthly caps (e.g., QL 150 EA per 30 days; QL 180 EA per 30 days for certain products).
    Invega Sustenna & Perseris QLsINVEGA SUSTENNA: QL stated as mL per 21 days (examples 0.25–1.5 mL/21 days); PERSERIS: QL 1 EA per 28 days.
    Aripiprazole and LAI QLsARISTADA/ERZOFRI/FANAPT LAI entries show QL in mL or ML per dosing interval (e.g., QL 1.5 mL per 21 days; QL 0.28–0.56 mL per 28–56 days).
    Stimulant per‑day QL examplesDextroamphetamine/Adderall/Mydayis entries commonly show QL (1–3 EA per day) or product‑specific per‑day limits (e.g., Zenzedi QL 2–4 EA per day).
    Quantity limits with varied dosing intervals
    Examples of QL expressed per variable daysFormulary includes QL in ML/EA per 21/28/30/42/70/166 day intervals (e.g., INVEGA SUSTENNA per 21 days; INVEGA TRINZA per 70 days/FL 90‑day fill).
    LAI antipsychotic QLsINVEGA SUSTENNA: QL values by strength (0.25–1.5 mL per 21 days); INVEGA TRINZA: QL per 70 days with FL: 90 days' supply per fill.
    FANAPT & ERZOFRI QLsFANAPT titration packs and ER injections specify QL (e.g., QL 8 EA per 28 days for titration pack; ERZOFRI QL 0.25–1.5 mL per 21 days depending on strength).
    COREG CR QL exampleCOREG CR (carvedilol phosphate ER) notes QL 1 EA per 1 day for the ER capsule formulation.
    Hemangeol & SOTYLIZE solution QLsHemangeol: QL 360 mL per 30 days; SOTYLIZE: QL 8 bottles in 30 days (with ST prerequisites where noted).
    Long‑acting injectables and inhalation QLs
    INVEGA SUSTENNA QL detailsINVEGA SUSTENNA intramuscular syringes: QL listed as mL per 21 days (e.g., 0.25, 0.5, 1.5 mL per 21 days by strength).
    PERSERIS QLPERSERIS (paliperidone long‑acting) QL 1 EA per 28 days.
    INVEGA TRINZA QL / FL noteINVEGA TRINZA: FL: 90 days' supply per fill; QL examples list mL per 70 days for various strengths.
    Nebulizer/inhalation solution QLsBROVANA/PERFOROMIST/PULMICORT nebulized solutions: QL 120 ML per 30 days (product dependent).
    Inhaler device QLsBREO/ADVAIR/ANORO/TRELEGY: QL commonly 60 EA per 30 days for inhaler/blister products.
    Selected product QL and per‑day examples
    Per‑day QL (1 EA per 1 day) examplesMultiple oral tablets (e.g., statins, ezetimibe combinations) and some ER capsules list QL 1 EA per 1 day.
    COREG CR QLCOREG CR (carvedilol phosphate ER) QL 1 EA per 1 day for ER capsule formulation.
    Enalapril/QBRELIS oral solution QLEPANED / QBRELIS oral solutions: QL 1200 ML per 30 days (ST/prior tablet requirement for certain ages).
    Hemangeol QL and STHemangeol: QL 360 mL per 30 days; ST requires prior propranolol oral solution within past 120 days for eligible ages.
    INVEGA SUSTENNA / TRINZA QLs — injectable scheduleINVEGA SUSTENNA: mL per 21 days by strength; INVEGA TRINZA: QL per 70 days with FL 90‑day supply per fill noted.
    Oral solution and cardiac drug QLs (including Hemangeol, SOTYLIZE)
    Hemangeol oral solution QLQL 360 mL per 30 days; ST: requires prior prescription for generic propranolol oral solution within past 120 days for patients ≥1 year.
    SOTYLIZE oral solution QLQL 8 bottles in 30 days; ST: prior prescription for sotalol tablets within past 120 days.
    EPANED / QBRELIS (enalapril) oral solution QLQL 1200 mL per 30 days; ST: may require prior prescription for corresponding tablets within past 120 days for patients ≥12 years.
    Furosemide formulations notedFurosemide appears as oral tablets (20/40/80 mg) and subcutaneous kit (FUROSCIX); QL examples reference ML/EA limits for solutions and supplies.
    Diltiazem and Norvasc (amlodipine) representationsDiltiazem: multiple ER formulations listed (Cardizem CD/LA, Cardizem LA, Tiazac etc.); Norvasc (amlodipine) strengths listed 2.5/5/10 mg in formulary entries.
    Formulations and quantity-limit units (inhaled, cardiac, diuretics)
    Inhaler/nebulizer ML and GM QLsExamples include QL expressed in GM or ML per 30 days (e.g., Pulmicort QL 120 ML per 30 days; AIRSUPRA QL 32.1 GM per 30 days; BREYNA QL 30.9 GM per 30 days).
    Diltiazem ER formulations documentedMultiple diltiazem extended‑release presentations listed (Cardizem CD/LA, Cardizem LA, TiaDylt ER) across strengths (120–420 mg ER).
    NORVASC (amlodipine) strengths listedAmlodipine (Norvasc) entries include strengths 2.5 mg, 5 mg, and 10 mg in the formulary.
    Furosemide forms presentFurosemide appears as FUROSCIX subcutaneous kit and oral tablets (Lasix) in strengths 20 mg, 40 mg, 80 mg; oral solution presentations referenced elsewhere in QL notes.
    Spironolactone and potassium‑sparing agentsSpironolactone listed as oral tablets (25/50/100 mg) and suspension (25 mg/5 mL), with typical tier notes in formulary entries.
    Consolidated QL examples with ST cross‑references
    DYMISTA QL and ST summaryDYMISTA nasal spray: QL 23 GM per 30 days; ST: prior prescription for flunisolide (nasal) or fluticasone within past 120 days required for coverage.
    SANCUSO patch QL and STSANCUSO transdermal patch: QL 1 EA per 7 days; ST: prior ondansetron tablets/ODT within past 120 days required.
    Nebulizer solution QLs — Brovana/PerforomistBROVANA and PERFOROMIST inhalation solutions: QL 120 ML per 30 days; some products have ST prerequisites (e.g., Brovana requires prior Perforomist/Serevent/Striverdi).
    INVEGA SUSTENNA / TRINZA QL highlightsINVEGA SUSTENNA LAI: QL specified as mL per 21 days by strength; INVEGA TRINZA: FL note for 90‑day supply per fill and QL reported per 70 days.
    Hemangeol & SOTYLIZE oral solution QLsHemangeol: QL 360 mL per 30 days (ST prior propranolol solution); SOTYLIZE: QL 8 bottles per 30 days (ST prior sotalol tablets).

    Prior Authorization, Step Therapy & Documentation Requirements

    Prior Authorization

    Obtain Prior Authorization for PA‑flagged agents

    Submit a Prior Authorization request when a drug line is marked “PA”; each request is reviewed against MedImpact P & T Committee guidelines and must meet those criteria for approval.

    • PA requires a specific physician request process prior to dispensing.
    • If the request does not meet P&T guidelines it will not be approved and an alternative may be recommended.
    Prior Authorization

    PA required for select allergen immunotherapy/specialty agents

    Obtain Prior Authorization for listed allergen immunotherapy and specialty products (e.g., Grastek, Odactra, Oralaire, Palforzia) before dispensing—these products are designated Notes = PA.

    • Examples: GRASTEK, ODACTRA, ORALAIR, multiple PALFORZIA levels are noted as PA in the formulary.
    Prior Authorization

    Follow PA/ST flags on specific products

    When a product’s Notes show ST or PA (for example Brovana, Perforomist, Serevent, Striverdi), obtain prior authorization or document required step‑therapy evidence prior to filling.

    • Brovana: ST requires prior prescription for Perforomist, Serevent, or Striverdi within past 120 days.
    • Multiple inhaled/ICS products list ST or PA in Notes; follow the specific product note.
    Prior Authorization

    Do not dispense PA‑designated products without approval

    Obtain prior authorization when Notes = PA on listed products such as EMSAM patch and other named agents; do not dispense without plan approval when PA is indicated.

    • EMSAM patch: Notes = ST/PA as specified (example shows ST requirement for prior MAOI within 120 days).
    • Products shown with Notes = PA must have PA submitted per plan process.
    Step Therapy

    Meet ST/PA requirements for stimulant and antipsychotic products

    For agents marked ST or PA (examples include certain stimulant and antipsychotic formulations), document prior comparator prescriptions or obtain PA before coverage.

    • DYANAVEL XR / XELSTRYM: ST requires prior prescription for Azstarys or Jornay PM within 120 days.
    • OPIPZA: ST requires prior generic aripiprazole within past 120 days.
    Prior Authorization

    Prior authorization required for listed CNS agents

    Submit PA for agents explicitly noted as PA (examples: LYBALVI, HETLIOZ, SUNOSI, ADDYI) and await plan decision before dispensing.

    • LYBALVI, HETLIOZ, SUNOSI, ADDYI are listed with Notes = PA in the formulary.
    Prior Authorization

    PA required for selected sleep/CNS products

    Obtain prior authorization for products designated PA in Notes (for example IGALMI sublingual film, QUVIVIQ) before dispensing.

    • IGALMI and QUVIVIQ are specifically annotated Notes = PA.
    Prior Authorization

    PA required for select cardiac/digitalis formulations

    When digitalis/digoxin presentations list Notes = PA, submit prior authorization per plan requirements before dispensing those formulations.

    • Digoxin tablets/solutions have Notes indicating PA for certain presentations.
    Prior Authorization

    Obtain PA for listed antihypertensive/alpha‑blocker agents

    Submit prior authorization for products whose Notes = PA (examples: phenoxybenzamine/Dibenzyline, VECAMYL) as indicated in the formulary before coverage will be granted.

    • DIBENZYLINE (phenoxybenzamine) and VECAMYL are listed with Notes = PA.
    Billing Rule

    Adhere to specified quantity limits (COREG CR example)

    Observe quantity limits when dispensing (example: COREG CR ER capsule has QL = 1 EA per 1 day); obtain PA if dispensing would exceed QL.

    • COREG CR (carvedilol phosphate ER) Notes = QL (1 EA per 1 day).
    Prior Authorization

    Obtain PA and satisfy ST prerequisites where indicated

    When a drug line is marked PA or ST, submit PA and/or document prior therapy evidence per the Notes—providers must obtain PA when Notes indicate 'PA' and comply with ST when 'ST' is specified.

    • Providers must obtain prior authorization when the formulary Notes designate 'PA'.
    • Providers must document prior prescriptions when Notes designate 'ST'.
    Prior Authorization

    PA required for numerous listed drugs

    Submit prior authorization for multiple drugs marked PA in the formulary; do not assume coverage without plan approval when Notes include PA.

    • Numerous listed drugs are annotated with Notes = PA and require PA prior to coverage.
    Prior Authorization

    Submit PA for select high‑tier specialty agents

    Prior authorization is required for high‑tier specialty agents (examples: CAMZYOS, ATTRUBY, VYNDAMAX, VYNDAQEL, VERQUVO); submit PA per plan process before dispensing.

    • CAMZYOS, ATTRUBY, VYNDAMAX, VYNDAQEL, VERQUVO are each shown with Notes = PA.
    Prior Authorization

    Prior authorization required for NORTHERA (droxidopa)

    NORTHERA (droxidopa) and listed formulations are designated Notes = PA—submit a prior authorization request before dispensing.

    • Droxidopa (NORTHE­RA) entries include Notes = PA.
    Note

    No explicit PA shown for listed contraceptives in this excerpt

    This extract does not list explicit PA requirements in the shown contraceptive section; follow general PA/ST guidance elsewhere in the formulary when Notes indicate a restriction.

    • Most contraceptive entries in this excerpt are marked Status = PREV; PA is not specified in these chunks.
    Note

    Follow PA process when status/Notes elsewhere require it

    Product statuses and quantity‑limit notes are shown in this excerpt without explicit PA for those specific NDCs—follow plan PA processes when PA is indicated elsewhere in the formulary.

    • Where Notes do not explicitly state PA, use standard prior authorization channels if coverage requires PA per other sections.
    Step Therapy

    Document prior generic clindamycin/BP gel for ACANYA

    ACANYA topical gel requires evidence of prior prescription for a generic clindamycin/benzoyl peroxide gel within the past 120 days before coverage (ST requirement).

    • ACANYA Notes = ST: Requires prior prescription for generic Clindamycin/Benzoyl Peroxide gel within past 120 days.
    Step Therapy

    Confirm and document Step Therapy requirements

    Step Therapy may apply when coverage depends on prior use of another drug; check the product Notes for ST and provide documentation of prior prescriptions where required.

    • ST indicators are denoted throughout the formulary and commonly require prior prescriptions within past 120 days.
    • If ST applies, prescribers must show prior trials of specified comparators per the Notes.
    Documentation Required

    Document prior trials for nasal/antihistamine STs

    Many nasal and antihistamine products carry ST requirements—document prior trials of the listed lower‑tier agents (commonly within 120 days) before requesting coverage for higher‑tier products.

    • Dymista: ST requires prior prescription for Flunisolide or Fluticasone within past 120 days; QL 23 GM per 30 days.
    • QNASL/XHANCE/ZETONNA list ST with specific intranasal corticosteroid comparators.
    Documentation Required

    Document prior comparator prescriptions for Brovana/Perforomist

    For products like Brovana and Perforomist, document a prior prescription for the specified comparator (Perforomist, Serevent, or Striverdi) within the past 120 days as required by ST notes.

    • Brovana Notes = ST: Requires prior prescription for Perforomist, Serevent, or Striverdi within past 120 days; QL (120 ML per 30 days).
    Documentation Required

    Support ST prerequisites with prior‑medication records (EMSAM example)

    When EMSAM and similar entries list ST prerequisites, provide documentation of the required prior medications within 120 days to satisfy ST before coverage.

    • EMSAM: ST requires prior prescription for Marplan, Phenelzine, or Tranylcypromine within past 120 days; QL (1 EA per 1 day).
    • AUVELITY/VIIBRYD require prior antidepressant trials within 120 days.
    Step Therapy

    Provide prior Azstarys/Jornay PM prescriptions for DYANAVEL/XELSTRYM

    DYANAVEL XR and XELSTRYM require documentation of prior prescription for Azstarys or Jornay PM within the past 120 days before approval under ST.

    • DYANAVEL XR / XELSTRYM Notes = ST: prior Azstarys or Jornay PM within 120 days; QL specified per product.
    Documentation Required

    Document prior generic hypnotic trials for hypnotic STs

    For hypnotics (e.g., Rozerem, tasimelteon), document required prior prescriptions (Eszopiclone, Zaleplon, or Zolpidem IR) within the past 120 days to meet ST.

    • ROZEREM and related entries note ST: prior Eszopiclone, Zaleplon, or Zolpidem IR within past 120 days.
    Documentation Required

    Supply prior‑use evidence for higher‑tier brand STs

    Many higher‑tier brand agents require evidence of prior prescriptions for listed generics/alternatives within the past 120 days; provide prescription history or clinical rationale when submitting PA.

    • ST entries commonly require prior use of specified alternatives within 120 days; prescribers must document those trials.
    Step Therapy

    Document prior ACE inhibitor/ARB trials for ARB combos

    For ARB combination products flagged with ST, document a prior prescription for an ACE inhibitor or ARB (or combination) within the past 120 days as required.

    • EDARBI/EDARBYCLOR: ST requires prior ACE inhibitor/ARB prescription within past 120 days.
    Documentation Required

    Include prior ACE/ARB prescriptions when required by ST

    Some ARB entries require prior ACE inhibitor/ARB prescription within 120 days; include those prescriptions in the PA/ST submission to avoid denial.

    • ST: prior ACE inhibitor/ARB within past 120 days is documented for specific ARB entries.
    Step Therapy

    Document prior statin or biologic therapy for PCSK9/ST requirements

    Specialty lipid agents (e.g., Repatha, Praluent) carry ST—document prior generic statin therapy (or prior biologic where specified) within the past 120 days before coverage.

    • Repatha: ST requires prior generic statin within past 120 days; Praluent: ST requires prior Repatha within past 120 days.
    Documentation Required

    Provide generic‑alternative trial records for Tier 4 STs

    For Tier 4 products flagged with ST, document trials of generic alternatives within the past 120 days (trial evidence required to satisfy step therapy prior to brand coverage).

    • Examples: Fenoglide/Lipofen require prior generic fenofibrate or gemfibrozil within past 120 days.
    Note

    No ST specified in this extract

    No step therapy rules are listed in the provided extract for these entries; follow other formulary Notes where ST or PA is indicated.

    • When ST is not specified in the chunk, standard coverage rules apply unless noted elsewhere.
    Note

    No ST specified in these contraceptive chunks

    No step therapy requirements are specified in these chunks; follow product Notes in other sections for ST or PA requirements.

    • These chunks focus on contraceptive status (PREV) and QL; ST is not listed here.
    Documentation Required

    Provide prior‑prescription proof for ACANYA (clindamycin/BP)

    ACANYA topical gel requires documentation of a prior prescription for generic clindamycin/benzoyl peroxide gel within 120 days before coverage; include those prior Rx records with any PA/ST submission.

    • ACANYA Notes = ST: Requires prior prescription for generic Clindamycin/Benzoyl Peroxide gel within past 120 days.
    Documentation Required

    How to submit a Prior Authorization to DHMP Pharmacy

    Fax a completed Prior Authorization Request to DHMP Pharmacy Department at (303) 602‑2081 or contact DHMP Pharmacy Department at (303) 602‑2070 and provide all requested information.

    • Use the DHMP Pharmacy Department fax number (303) 602‑2081 to submit PA requests.
    • For questions or additional information call (303) 602‑2070.
    Documentation Required

    Document prior prescriptions to satisfy ST flags

    When a product is flagged ST, document prior prescriptions supporting the step‑therapy requirement (examples: desloratadine/levocetirizine trials for CLARINEX‑D ER and similar entries).

    • CLARINEX‑D ER Notes = ST: Requires prior prescription for Desloratadine or Levocetirizine within past 120 days.
    Prior Authorization

    Submit PA for listed biologics and include clinical justification

    PA is required for multiple biologics (e.g., DUPIXENT, FASENRA, XOLAIR, NUCALA, CINQAIR); submit PA and include clinical documentation supporting biologic use.

    • DUPIXENT and related IL‑4/IL‑5 biologics list Notes = PA and require PA submission.
    Documentation Required

    Include 120‑day prior prescription history when ST applies

    When ST is indicated, documentation must support prior prescriptions within the past 120 days (e.g., prior antidepressant or comparator drug prescriptions) to satisfy step therapy.

    • Examples include prior antidepressant prescriptions for AUVELITY/VIIBRYD and other ST entries requiring 120‑day look‑back.
    Documentation Required

    Document prior medication history for ST examples (DYANAVEL/XELSTRYM)

    Provide prior medication history when ST is required (e.g., Azstarys/Jornay PM evidence for DYANAVEL XR/XELSTRYM) and include those records with PA or claims.

    • DYANAVEL XR/XELSTRYM: ST requires prior Azstarys or Jornay PM within 120 days.
    • OPIPZA: ST requires prior generic aripiprazole within 120 days.
    Billing Rule

    Respect QL restrictions for long‑acting injectables

    Observe quantity limits for long‑acting injectables and other products (e.g., Invega Sustenna, Perseris, Invega Trinza have explicit QL per dosing interval) when submitting claims.

    • INVEGA SUSTENNA Notes = QL (0.75 mL per 21 days) for 117 mg/0.75 mL syringe example.
    • PERSERIS Notes = QL (1 EA per 28 days).
    Documentation Required

    Document prior therapies per ST Notes

    When a product's Notes specify 'ST', prescribers must show evidence of prior prescriptions for the listed alternatives (commonly within 120 days); include those prescriptions in the PA/claim.

    • ST notes frequently state 'Requires prior prescription for [listed alternatives] within the past 120 days'—provide supporting prescriptions.
    Documentation Required

    Provide prior prescription evidence for specialty oral solutions

    For specialty oral solutions and other oral solution entries that include ST/QL notes, include supporting prescriptions and observe the stated QL (e.g., EPANED/QBRELIS require prior enalapril tablet Rx if patient ≥12 years).

    • EPANED/QBRELIS Notes = ST: prior Enalapril tablets within past 120 days if ≥12 years; QL (1200 mL per 30 days).
    Documentation Required

    Provide proof of prior therapy when ST/PA indicated

    When ST or PA notes are listed, prescriptions supporting prior therapy or prior prescription history may be required; include those prescriptions or clinical rationale to avoid denial.

    • Example: SOTYLIZE requires prior sotalol tablets within 120 days; other entries require ACE inhibitor/ARB or beta‑blocker trials.
    Documentation Required

    Support QL/ST with documentation to avoid denial

    When QL or ST is specified, include documentation supporting prior prescriptions or clinical rationale with the PA to reduce denial risk (e.g., QL = 1 EA per 1 day requires appropriate claim documentation).

    • Claims exceeding QL or missing ST evidence may be denied or require PA; support QL/ST with documentation.
    Documentation Required

    Document prior beta‑blocker trial for ivabradine (Corlanor)

    For ivabradine (Corlanor), document a prior prescription for Bisoprolol, Carvedilol, or Metoprolol Succinate within the past 120 days (ST requirement) and observe the QL (2 tablets per day).

    • Corlanor Notes = ST: Requires prior Bisoprolol, Carvedilol, or Metoprolol Succinate within past 120 days; QL (2 EA per 1 day).
    Billing Rule

    Adhere to explicit QL values on dispensing claims

    Observe specified quantity limits when dispensing (examples shown include 91 EA per 84 days; 28 EA per 28 days; 1 EA per 1 day) and document adherence to QL on claims.

    • Common QL examples: 91 EA per 84 days (3‑month packs), 28 EA per 28 days (monthly packs), 1 EA per 1 day for many tablets.
    Denial Risk

    Risk of denial if PA criteria are unmet

    Denials will occur for PA requests that do not meet MedImpact P & T Committee guidelines; alternative therapy may be recommended if PA criteria are not satisfied.

    • Requests failing to meet P&T guidelines will not be approved.
    • Providers may appeal non‑approved requests with supporting medical necessity information.
    Denial Risk

    Denial risk when ST prior agents not documented

    Failure to document prior trials required by step therapy (e.g., missing required 120‑day prior prescriptions) may result in utilization management denials.

    • Dymista and other ST entries require prior comparator prescriptions within 120 days; absence of these records can trigger denial.
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Initial Therapy & Prior-Prescription Requirements

    ProductStep therapy requirement
    CLARINEX-D 12 HOUR ORAL TABLET (desloratadine-chlorpheniramine) — ER multiphase 2.5–120 mgST: Requires prior prescription for Desloratadine or Levocetirizine tablets within the past 120 days
    Example product / classRequired prior trial(s) (look‑back period)
    Desloratadine / Levocetirizine products (oral disintegrating tablets, solutions)ST: Requires prior prescription for Desloratadine or Levocetirizine tablets within the past 120 days
    DYMISTA (azelastine–fluticasone nasal spray)ST: Requires prior prescription for Flunisolide (nasal) or Fluticasone within the past 120 days; QL (23 GM per 30 days)
    QNASL / XHANCE / ZETONNA (intranasal corticosteroid/unique delivery)ST: Requires prior prescription for Flunisolide, Fluticasone, or Mometasone within the past 120 days; product‑specific QL applies
    Dronabinol (Marinol) / SyndrosST: Requires prior prescription for a 5HT3 antagonist, corticosteroid, Emend (aprepitant), or Megestrol suspension within the past 120 days; QL noted per product
    Various branded higher‑tier agents (general)ST: Requires trial of listed lower‑tier or specified comparator agents within the past 120 days before coverage of branded/higher‑tier products
    ProductStep therapy requirement
    BROVANA inhalation solution for nebulization (arformoterol) 15 mcg/2 mLST: Requires prior prescription for Perforomist (formoterol), Serevent (salmeterol), or Striverdi within the past 120 days; QL (120 ML per 30 days)
    Product / classStep therapy requirement
    Combination inhalers and inhaled corticosteroid (e.g., ADVAIR, BREO ELLIPTA, WIXELA, SYMBICORT, BREYNA)ST: Some combination inhalers require prior prescription for Advair HFA or BreoEllipta within the past 120 days; product‑specific QL applies (e.g., 60 EA per 30 days)
    Arnuity Ellipta / related ICS products (e.g., ALVESCO, ASMANEX)ST: Certain ICS products list ST: Requires prior prescription for Arnuity Ellipta within the past 120 days (product QL where noted)
    ProductStep therapy requirement
    ARNUITY ELLIPTA (fluticasone furoate) and some ICS entriesST: Requires prior prescription for Arnuity Ellipta within the past 120 days; QL noted per product (example: Arnuity QL 30 EA per 30 days)
    Product / exampleStep therapy requirement
    EMSAM transdermal patch (selegiline) and other MAOI entriesST: Requires prior prescription for Marplan, Phenelzine, or Tranylcypromine within the past 120 days; QL where noted (e.g., 1 EA per 1 day)
    AUVELITY / VIIBRYD and selected antidepressantsST: Requires prior prescriptions for listed antidepressants (examples include bupropion, citalopram, escitalopram, fluoxetine, paroxetine, sertraline, venlafaxine, etc.) within the past 120 days
    ProductStep therapy requirement
    DYANAVEL XR (oral suspension) and XELSTRYM (transdermal patch)ST: Requires prior prescription for Azstarys or Jornay PM within the past 120 days; product‑specific QL applies (e.g., DYANAVEL XR QL 240 mL per 30 days for suspension)
    XELSTRYM transdermal patchST: Requires prior prescription for Azstarys or Jornay PM within the past 120 days; QL (1 EA per 1 day)
    Product / groupStep therapy requirement
    Hypnotics and related agents (e.g., Rozerem, tasimelteon, Belsomra, Dayvigo, doxepin entries)ST: Requires prior prescription for Eszopiclone, Zaleplon, or Zolpidem IR (or other specified generics per entry) within the past 120 days; QL commonly 1 EA per day where noted
    ZENZEDI (dextroamphetamine) examplesST: For specific stimulant/hypnotic cross‑references entries may require prior dextroamphetamine IR tablets or solutions within past 120 days (as listed)
    Higher‑tier product exampleRequired alternative(s) tried within look‑back
    BELSOMRA, DAYVIGO, other higher‑tier sleep agentsST: Requires prior prescription for Eszopiclone, Zaleplon, or Zolpidem within the past 120 days; QL typically 1 EA per day
    OPIPZA (oral film) and certain antipsychotic/brand formulationsST: Requires prior prescription for generic aripiprazole tablets within the past 120 days before coverage
    ADHD branded products (examples: Cotempla, Aptensio, Qullichew)ST: Requires prior prescription for methylphenidate ER/LA/CD or listed comparators (e.g., Azstarys, Jornay PM, generic lisdexamfetamine) within the past 120 days
    Product / classStep therapy requirement
    EDARBI and other ARB combination productsST: Requires prior prescription for an ACE inhibitor, ACE inhibitor combination, ARB, or ARB combination within the past 120 days
    Select combination ARB products (EDARBYCLOR, EDARBI examples)ST: Prior ACE inhibitor/ARB therapy within 120 days is required before coverage
    ProductRequired prior prescription
    Hemangeol oral solution (propranolol 4.28 mg/mL)ST: Requires prior prescription for generic propranolol oral solution within the past 120 days if patient is ≥1 year of age; QL (360 mL per 30 days)
    SOTYLIZE oral solution 5 mg/mLST: Requires prior prescription for sotalol tablets within the past 120 days; QL: 8 bottles in 30 days
    ARB product exampleStep therapy requirement
    EDARBI (azilsartan) and selected ARB entriesST: Requires prior prescription for an ACE inhibitor, ACE inhibitor combination, ARB, or ARB combination within the past 120 days
    Specialty biologic examplePrior therapy required
    REPATHA (evolocumab) productsST: Requires prior prescription for a generic statin within the past 120 days before Repatha coverage (product‑specific QL may apply)
    PRALUENT (alirocumab) penST: Requires prior prescription for Repatha within the past 120 days before Praluent coverage
    Product / classStep therapy requirement
    FENOGLIDE / Lipofen / other branded fenofibrate productsST: Requires prior prescription for generic fenofibrate or gemfibrozil within the past 120 days before coverage
    ProductStep therapy requirement
    CORLANOR (ivabradine) oral tablet / solutionST: Requires prior prescription for Bisoprolol, Carvedilol, or Metoprolol Succinate within the past 120 days; QL (2 EA per 1 day for tablets; solution QL as noted)
    Scope / general ruleTypical requirement
    Generics and lower‑tier comparator requirement (general ST rule)ST: Many branded/higher‑tier products require documented prior prescription(s) for specified generic or comparator agents within the past 120 days before coverage; documentation of prior prescriptions must be provided to satisfy ST
    When no ST is specifiedSome products in the formulary do not list step therapy requirements — coverage follows tier and PA rules where applicable
    NoteContent
    Step therapy rules absent (example chunk)No step therapy requirements are specified in these chunks
    ProductStep therapy requirement
    ACANYA topical gel with pump (clindamycin–benzoyl peroxide) 1.2–2.5%ST: Requires prior prescription for generic clindamycin/benzoyl peroxide gel within the past 120 days; QL (30 mL per 1 day) and age minimums where noted

    Quantity Limits & Supply Restrictions

    Specialty medications — supply maximum
    Specialty medications supply limitTier 5 specialty medications: 30‑day supply maximum
    Tier placementSpecialty products placed in Tier 5 (30‑day supply max) or Tier 6 for medical benefit items
    Coverage implicationSpecialty tiering indicates utilization controls such as PA and QL apply per formulary notes
    DYMISTA quantity limit example
    Dymista (azelastine‑fluticasone) — exampleQL 23 GM per 30 days; ST: requires prior prescription for flunisolide or fluticasone within past 120 days
    Status and tieringDymista listed with Tier 2 (product‑ and brand‑level variants may differ)
    Provider action implicationST requirement means prior prescription documentation for comparator intranasal steroid is needed for approval
    SANCUSO quantity limit example
    Sancuso (granisetron transdermal patch)QL 1 EA per 7 days; ST: requires prior prescription for ondansetron tablets/ODT within past 120 days
    Weekly patch QLPatch dosing reflected as EA per 7 days in QL notation
    TieringSancuso listed as Tier 4 in the formulary extract
    SPIRIVA WITH HANDIHALER quantity limit example
    Spiriva with HandiHalerQL 30 EA per 30 days (tiotropium inhalation capsules with HandiHaler)
    Spiriva RespimatRespimat formulations list QL (4 GM per 30 days) for certain strengths
    Related inhaler QLsProvider should observe device‑specific QLs when dispensing inhaled anticholinergics
    BROVANA / PERFOROMIST / Pulmicort QL examples
    Brovana inhalation solutionQL 120 ML per 30 days (arformoterol nebulization) — ST: requires prior prescription for Perforomist/Serevent/Striverdi within past 120 days
    Perforomist inhalation solutionQL 120 ML per 30 days (formoterol fumarate nebulization)
    Pulmicort nebulizationQL 120 ML per 30 days (budesonide inhalation suspension) as noted in Pulmicort entry
    ANORO ELLIPTA QL example
    Anoro Ellipta inhalation blisterQL 60 EA per 30 days (umeclidinium‑vilanterol blister with device)
    Bevespi AerosphereNotes include ST and QL (product‑specific GM per 30 days) for some combination inhalers
    Duaklir / Combivent examplesSome combination inhalers list QL 1 EA per 30 days or device‑specific counts as noted
    ADVAIR DISKUS QL example
    Advair Diskus inhalation blisterQL 60 EA per 30 days
    AirDuo / Breo / TrelegyRelated combination ICS/LABA entries list QL values (e.g., AirDuo QL 1 EA per 30 days; Breo QL 60 EA/30 days; Trelegy QL 60 EA/30 days)
    Device countingBe mindful that QL may be expressed as EA (device count) or GM/ML depending on product form
    BREO ELLIPTA QL example
    Breo Ellipta inhalation blisterQL 60 EA per 30 days (fluticasone furoate‑vilanterol entries list 60 EA/30 days)
    Breyne / BreynaSome HFA inhalers list GM per 30 days (e.g., Breyna QL ~30.9 GM per 30 days)
    Provider noteQLs differ by formulation and strength; use the product line QL when dispensing
    TRELEGY ELLIPTA QL examples
    Trelegy ElliptaQL 60 EA per 30 days (100‑62.5‑25); some strengths list QL 2 EA per 1 day for alternate strengths
    Breztri AerosphereQL 10.7 GM per 30 days noted for some combination inhalers
    Variable QLs by strengthTrelegy entries include both per‑30‑day EA limits and per‑day EA limits for different strengths
    Pulmicort nebulization QL example
    Pulmicort nebulization (budesonide)QL 120 ML per 30 days (Pulmicort inhalation suspension for nebulization)
    QVAR RediHalerQL 21.2 GM per 30 days noted for some HFA breath‑activated devices
    Arnuity/Pulmicort ST notesSeveral ICS products have ST requiring prior prescription for Arnuity Ellipta within past 120 days in addition to QL
    Various product‑specific QL examples (EA/day, EA/30 days, ML/30 days)
    Per‑day EA examplesMultiple entries show QL 1 EA per 1 day or 2 EA per 1 day for specific tablets and titration packs
    High monthly EA examplesExamples include QL 150 EA per 30 days (methamphetamine) and QL 180 EA per 30 days for other products
    Liquid volume examplesSome oral solutions and suspensions list large ML QLs (e.g., Procetra/Procentra/Quillivant volumes) per 30 days
    Sedative‑hypnotics and sleep agents QL examples
    Sedative‑hypnotics QLMany sedative‑hypnotic and sleep agent entries list QL 1 EA per 1 day (e.g., Ambien, Lunesta, eszopiclone entries)
    ST requirements for hypnoticsSeveral hypnotics require prior prescription for listed generics within past 120 days as ST condition
    PA flags for some agentsCertain newer agents (e.g., Quviviq) are also noted as PA in formulary entries
    ADHD product quantity‑limit examples
    ADHD product QLsADHD products commonly show QL 1–3 EA per day or product‑specific limits (many ER products QL 1 EA/day)
    Patch & suspension volumesTransdermal patches and suspensions have product‑specific QLs (e.g., Daytrana QL 1 EA/day; Quillivant bottle volumes)
    Step therapy impactMultiple ADHD brands include ST requiring prior prescriptions for generic methylphenidate/lisdexamfetamine within past 120 days
    Stimulant suspension bottle‑volume QL examples
    Stimulant suspension bottle volumesQuillivant XR and similar suspensions list bottle‑volume QLs of 60–360 mL per 30 days depending on packaging
    Packaging‑dependent QLDifferent bottle sizes have distinct QLs (e.g., 60 mL, 120 mL, 180 mL, 240 mL, 300 mL, 360 mL entries)
    ST referencesST notes often accompany suspension QLs, requiring prior prescriptions for listed alternatives within 120 days
    COREG CR quantity‑limit example
    COREG CR (carvedilol phosphate ER)QL 1 EA per 1 day (documented QL example) — applies to ER capsule formulation
    ENALAPRIL oral solution QL example
    Enalapril oral solutions (EPANED/QBRELIS)QL 1200 ML per 30 days; ST: requires prior prescription for corresponding tablet (lisinopril/enalapril) within past 120 days if ≥12 years
    Provider documentationPrior prescription history for tablet form may be required to support oral solution dispensing
    TieringOral solution forms are usually Tier 4 with QL noted
    Hemangeol — quantity limit
    Hemangeol oral solutionQL 360 mL per 30 days; ST: requires prior prescription for propranolol oral solution within past 120 days (if 1 year or older)
    SOTYLIZE — quantity limit
    Sotylize oral solution (5 mg/mL)QL 8 bottles in 30 days; ST: requires prior prescription for sotalol tablets within past 120 days
    Statin and Zetia QL examples
    Statins / combination productsMultiple statin and ezetimibe‑simvastatin entries show QL 1 EA per 1 day (e.g., Vytorin entries) — observe QL when dispensing
    Zetia (ezetimibe)QL 1 EA per 1 day listed for Zetia oral tablet 10 mg
    PA/ST notesSome lipid products also carry ST or PA requirements in addition to QL
    Ranolazine and Vascepa QL examples
    Ranolazine ER 1000 mgQL 60 EA per 30 days
    Ranolazine ER 500 mgQL 120 EA per 30 days
    Vascepa 0.5 g / 1 gVascepa 0.5 g QL 8 EA per day; Vascepa 1 g QL 4 EA per day (documented product QLs)
    Depo‑Provera / Depo‑SubQ QL examples
    Depo‑Provera IM suspension 150 mg/mLQL 1 ML per 84 days (Depo‑Provera intramuscular) — Status = PREV
    Depo‑SubQ Provera 104QL 0.65 ML per 84 days (subcutaneous syringe) — Status = PREV
    Injectable contraceptive QLProvider should follow QL per 84‑day dosing interval for injectable contraceptives
    Oral contraceptive pack quantity limits
    3‑month oral contraceptive packsQL 91 EA per 84 days for many 3‑month dose‑packs (e.g., Ashlyna, Camrese Lo, JoLessa) — Status = PREV
    Monthly 28‑day packsQL 28 EA per 28 days for many 28‑day packs (e.g., Minzoya, Slynd) — Status = PREV
    Single‑tablet daily regimensSome products (e.g., Nextstellis) list QL 1 EA per 1 day
    Camrese Lo — 3‑month pack QL
    Camrese Lo 3‑month packQL 91 tablets per 84 days (Camrese Lo and similar 3‑month packs) — Status = PREV
    Provider dispensing noteThree‑month packs are dispensed consistent with QL 91 EA/84 days where listed
    Status flagMost contraceptive entries show Status = PREV (preventive coverage) alongside QL
    Minzoya — 28‑day pack QL
    Minzoya and similar 28‑day packsQL 28 tablets per 28 days — Status = PREV
    Common 28‑day QLMany 28‑day formulation packs follow QL 28 EA/28 days in contraceptive listings
    Pharmacy actionDispense per pack‑specific QL when submitting claims
    Nextstellis — quantity limit
    NextstellisQL 1 EA per 1 day (Nextstellis oral tablet) — Status = PREV
    Daily tablet QLSingle‑tablet daily contraceptives are represented as QL 1 EA per day in formulary entries
    Coverage implicationPrescribers should expect claims to follow the 1‑per‑day QL for single‑tablet contraceptives
    Slynd — quantity limit
    SlyndQL 28 tablets per 28 days — Status = PREV
    Pack‑based QLSlynd and similar monthly packs list the 28‑day QL explicitly in notes
    Provider reminderFollow QL when processing contraceptive claims to ensure preventive coverage handling
    Methylergonovine — quantity limit
    Methylergonovine (oral tablet 0.2 mg)QL 28 EA per 30 days (documented QL for methylergonovine)
    Clinical categoryListed under Oxytocics with QL and tiering specified
    Dispensing noteObserve 28 EA/30 day QL when dispensing oral methylergonovine tablets
    Syrup and controlled cough product QLs
    Promethazine‑codeine syrupQL 30 ML per 1 day; Age (Min 18 Years) indicated for controlled syrup dispensing
    Hydrocodone‑chlorpheniramine oral suspensionQL 10 ML per 1 day; Age (Min 18 Years) applies
    Hydrocodone‑homatropine productsQL 6 EA per 1 day for tablet forms; age minimums also noted where applicable

    Policy Governance & Rationale

    The formulary and therapeutic review are overseen by the plan’s pharmacy and therapeutics process. The MedImpact P & T and Formulary Committees evaluate drugs for safety, efficacy, therapeutic benefit relative to formulary agents, and cost‑effectiveness to maintain access to clinically appropriate therapies and to inform utilization controls such as PA, ST, and QL.

    Key Terms & Abbreviations

    Definition — Prior Authorization (PA)
    Prior Authorization (PA)Requires plan approval before coverage — prescriber must submit a PA request (per formulary notes)
    How to submit PAFax a completed Prior Authorization Request to DHMP Pharmacy Department at (303) 602-2081 or contact DHMP Pharmacy Department at (303) 602-2070 (documented contact)
    Denial riskRequests not meeting P&T Committee guidelines will not be approved
    Definition — Quantity Limit (QL)
    Quantity Limit (QL)A restriction on the amount dispensed per specified time period (examples include EA per day or ML per 30 days, e.g., QL 1 EA per 1 day; QL 120 ML per 30 days)
    PurposeUsed to control dispensing quantity for safety, cost, and adherence to formulary rules
    Examples in documentDocumented examples include per‑day (1 EA/day), per‑30‑day (120 ML/30 days), per‑84‑day (91 EA/84 days) limits
    Definition — Step Therapy (ST)
    Step Therapy (ST)Coverage may depend on prior prescription(s) for specified alternative agents within a defined look‑back period (commonly 120 days) before approval
    Common look‑backST commonly requires prior prescriptions within the past 120 days for listed comparators (e.g., inhaled corticosteroids, ADHD agents, hypnotics)
    DocumentationProviders must document prior prescriptions to satisfy ST when noted in formulary entries
    Definition — Age / Gender dependencies
    AGE / G (age/gender edits)Coverage may depend on patient age (AGE) or gender (G) as denoted in prescribing guidelines (examples: minimum age 18 years for certain antitussives)
    ExamplesEntries show Age (Min 2 Years) for some pediatric antihistamine liquids and Age (Min 18 Years) for controlled syrups
    Implication for claimsClaims should respect age/gender edits where specified to avoid denial
    ST — look‑back period and requirement
    ST look‑back requirementStep Therapy typically requires prior prescriptions for listed alternatives within past 120 days to meet ST criteria
    ExamplesMarinol/Syndros entries require prior trials of 5HT3 antagonist/corticosteroid/Emend or megestrol within 120 days; many nasal products require intranasal steroid prior trial within 120 days
    Documentation neededPharmacies/providers should provide prior prescription history to support ST at PA review
    Quantity Limit (QL) — examples and usage
    QL examples formatQuantity limits appear as EA per days or ML per days (e.g., 1 EA per 1 day; 120 ML per 30 days; 91 EA per 84 days)
    Multiple examples presentDocument contains numerous QL examples across classes — inhalers, injectables, tablets, solutions, contraceptives
    InterpretationUse the exact product QL specified in the formulary entry when adjudicating or dispensing
    Contraceptive QL examples repeated
    Examples captured inline: QL 91 EA per 84 days for 3‑month packs; QL 28 EA per 28 days for 28‑day packs; QL 1 EA per 1 day for daily tablets like Nextstellis.